Immunohistochemical Characterization of Genes Expressed in Leiomyoma using Ki67 and P53 in Patient Attending Niger Delta University Teaching Hospital
Journal of Cancer and Tumor International,
Objectives: This study aimed to investigate the expressions of p53 and ki67 genes in the characterization of leiomyomas.
Materials: Fifty (50) Paraffin embedded tissue blocks were selected from the department of Histopathology, Niger Delta University Teaching Hospital, Okolobri from January 2011 to August 2019. The histological characterization and morphological evaluation were defined using the routine Hematoxylin and Eosin staining method. Immunostaining was done for p53 and ki67 using the manufacturers antibodies.
Results: A direct correlation between age and the expression of the p53 gene was also made in this study. It was observed that in patients within the ages of 50-59 and 60-69, there was markedly no expression of the p53 gene whereas in patients within the ages of 20-29, there was still some level of expression (20%) and ages 30-39 (80%) and finally 40-49 (10%). There was no expression (0.0%) of Ki-67 in uterine leiomyomas across all age groups.
Conclusion; This study therefore has suggested that based on the percentage of expression, it can rightly be inferred that the p53 gene is a good indicator in the immune-histochemical characterization of leiomyomas as it has good sensitivity and good prognosis as opposed to Ki67.
How to Cite
Rammeh-Rommani S, Mokni M, Stita W, Trabelsi A, Hamissa S, Sriha B, Tahar-Yacoubi M. Journal of Gynecology and Obstetrics Biological Reproduction. 2005;34:568-7.
Ünver NU, Acikalin MF, Öner Ü, Ciftci E, Ozalp SS, Colak E. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecology Obstetrics. 2011;284 (2):483-90.
Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Bohling T, Koski TA, Launonen V, Sjoberg J, Taipale J, Vahteristo P, Aaltonen LA. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053) :252-5.
O'neill C, McBride H, Connolly L, McCluggage W . Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007;50(7):851–8.
Gökaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59:36-40.
Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril. 2004;81:1062-6.
Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Human Pathology. 2001;32:984-7.
Ramos-Vara JA. Technical Aspects of Immunohistochemistry. Veterinary Pathology. 2005;42(4): 405–426.
Zhijian G, Hiroya M, Satoshi N, Osamu K, Takeshi M (). p53 Tumor Suppressor Protein Content in Human Uterine Leiomyomas and its Down-Regulation by 17β- Estradiol. The Journal of Clinical Endocrinology & Metabolism. 2002;87(8):3915-3920
Layfield LJ, Liu K, Dodge R, Barsky SH. Uterine smooth muscle tumors: utility of classification by proliferation, ploidity, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med. 2000;124:221–7.
Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: An international internet-based survey of 21,746 women. BMC women's health. 2012;12(1):6-8.
Zalondex CJ, Hendricksen CJ. Mesenchymal tumors of the uterus. Blaustein's pathology of the female genital tract. Edited by: Kurman RJ. Spinger, New York. 2002;561-615.
Blagosklonny VM. P53;An ubiquitous target of anticancer drugs. International Journal of Cancer. 2001;98(2):161-166.
Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave processed formalin‐fixed paraffin sections. Journal of Pathology. 1992;168: 357–63.
Chou CY, Huang SC, Tsai YC, Hsu KF, Huang KE. Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecology and Oncology. 1997;65:225–31.
Zhai YL, Nikaido T, Shizawa T, Orii A, Fujii S. Expressions of cyclins and cyclin dependent kinases in smooth muscle tumors of the uterus. International Journal for Cancer. 1999;84:244-50.
Klaus Bodner, Barbara B, Oliver K, Klaus C, Klaus M. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertility and Sterility. 2009;8(4):1062-1066.
Abstract View: 109 times
PDF Download: 63 times